NXP900

A Fast Method to Monitor Tyrosine Kinase Inhibitor Mechanisms
(Journal of Med. Chem. 2024)
NXP900 demonstrates potent synergy with ALK inhibitors in ALK resistant cell lines (ENA 2024)
A multi-omics approach to identify biomarkers of response to NXP900 (ENA 2024)
NXP900 demonstrates potent inhibition of proliferation in cell lines resistant to ALK and EGFR inhibitors (AACR 2024)
NXP900 inhibits YAP1 nuclear localization and tumor growth in esophageal squamous cancers
(ENA 2023)
Differences in target inhibition and anticancer efficacy between NXP900 and dasatinib
(AACR 2023)
Macrophages promote anti-androgen resistance in prostate cancer bone disease
(Journal of Exp. Med. 2023)
Screening of NXP900 and dasatinib identifies differences in their antiproliferative activity (ENA 2022)
Uncovering the molecular mechanisms which predict sensitivity to NXP900
(AACR 2022)
Loss of Integrin-linked kinase sensitizes breast cancer to SRC inhibitors
(Cancer Res. 2021)
A conformation selective mode of inhibiting SRC improves drug efficacy and tolerability
(Cancer Res. 2021)